Roth Mkm Reiterates Buy Rating for TriSalus Life Sciences (NASDAQ:TLSI)

Roth Mkm reaffirmed their buy rating on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a research note issued to investors on Friday,Benzinga reports. They currently have a $11.00 price objective on the stock.

Other research analysts also recently issued research reports about the stock. Canaccord Genuity Group reduced their price target on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Cantor Fitzgerald started coverage on shares of TriSalus Life Sciences in a research note on Tuesday, December 17th. They set an “overweight” rating and a $10.00 price target on the stock. Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Northland Securities assumed coverage on TriSalus Life Sciences in a research report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price objective on the stock. Finally, Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, TriSalus Life Sciences presently has a consensus rating of “Buy” and an average target price of $11.79.

TriSalus Life Sciences Trading Up 0.4 %

Shares of TLSI opened at $5.18 on Friday. The stock has a fifty day moving average price of $4.48 and a two-hundred day moving average price of $4.77. TriSalus Life Sciences has a 52-week low of $3.50 and a 52-week high of $10.42.

Insider Buying and Selling at TriSalus Life Sciences

In related news, major shareholder Equity Ab Frankenius bought 62,972 shares of TriSalus Life Sciences stock in a transaction on Tuesday, December 17th. The shares were purchased at an average price of $3.97 per share, for a total transaction of $249,998.84. Following the completion of the acquisition, the insider now owns 6,230,748 shares in the company, valued at approximately $24,736,069.56. This represents a 1.02 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders acquired 70,012 shares of company stock worth $281,235. Insiders own 32.80% of the company’s stock.

Institutional Trading of TriSalus Life Sciences

A number of hedge funds have recently modified their holdings of TLSI. Walleye Capital LLC bought a new stake in TriSalus Life Sciences in the third quarter valued at approximately $66,000. MSD Partners L.P. acquired a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at $184,000. Vestcor Inc bought a new stake in shares of TriSalus Life Sciences in the 3rd quarter valued at $108,000. Geode Capital Management LLC raised its stake in TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after buying an additional 62,542 shares during the period. Finally, Virtu Financial LLC bought a new position in TriSalus Life Sciences during the third quarter worth about $92,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.